

990-PF

Return of Private Foundation

OMB No. 1545-0082

Department of the Treasury
Internal Revenue Service

or Section 4947(a)(1) Trust Treated as a Private Foundation

Note: You may be able to use a copy of this return to satisfy State reporting requirements.

1984

For the calendar year 1984, or tax year beginning

, 1984, and ending

, 19

Please type,
print, or
attach label.
See Specific
Instructions.

Name of organization

THE KROG FOUNDATION

Employer identification number

36 6125259

Address (number and street)

5100 8939 YILLA LA JOLLA DRIVE, SUITE 201

State registration number (see instructions)

CA 0578112

City or town, State, and ZIP code

LA JOLLA CA 92037

Fair market value of assets at end of year

10973543

If application pending, check here ☐If address changed, check here ☒Foreign organizations, check here ☐

Check type of organization

☒ Exempt private foundation☐ 4947(a)(1) trust☐ Other taxable private foundationIf the foundation is in a 60-month
termination under section
507(b)(1)(B) check here ☐Section 4947(a)(1) trusts filing this form in lieu of Form 1041, check here and see General Instructions. ☐The books are in care of ☒ Certified Public AccountantLocated at ☒ 401 West 4th St. 4th Floor San Diego, CA 92101 Telephone no. ☒ (619) 532-8000Check this box if your private foundation status terminated under
section 507(b)(1)(A) ☐Analysis of Revenue and Expenses
(See Instructions for Part I)(A) Revenue and
expenses per
books(B) Net investment
income(C) Adjusted net
income(D) Disbursements
for charitable
purpose

Revenue	1	Contributions, gifts, grants, etc. received (attach schedule)	1077876			
	2	Contributions from split-interest trusts				
	3	Interest on savings and temporary cash investments	1030835	1030835	1030835	
	4	Dividends and interest from securities	66622	66622	66622	
	5	Gross rents				
	6	Net gain or (loss) from sale of assets not on line 10	243704			
	7	Capital gain net income		243704		
	8	Net short-term capital gain				
	9	Income modifications				
	10	Gross profit from any business activities: (Gross receipts <input checked="" type="checkbox"/> \$ minus cost of sales <input checked="" type="checkbox"/> \$)				
	11	Other income (attach schedule) <input checked="" type="checkbox"/> See 2	39588	34	34	
	12	Total (add lines 1 through 11)	2458625	134195	1097491	
Operating and Administrative Expenses	13	Compensation of officers, directors, trustees, etc.	70000	14000	14000	56000
	14	Other employee salaries and wages	129682	24127	24127	24127
	15	Pension plans, employee benefits	9046	1809	1809	7227
	16	(a) Legal fees	2147	429	429	-
		(b) Accounting fees	22024	4406	4406	-
		(c) Other professional fees	1067	213	213	-
	17	Interest	4	-	-	-
	18	Taxes (attach schedule) <input checked="" type="checkbox"/> See 2	37112	2250	2250	1999
	19	Depreciation and depletion	9386	-	9386	
	20	Occupancy	14162	-	14162	-
	21	Travel, conferences, and meetings	132074	7929	7929	124145
	22	Printing and publications	258041	-	-	258041
	23	Other expenses (attach schedule) <input checked="" type="checkbox"/> See 2	60505	3278	3278	31961
	24	Total operating and administrative expenses (add lines 13 through 23)	745250	58441	11989	510510
	25	Contributions, gifts, grants paid (from Part XIII) <input checked="" type="checkbox"/> See 1	4382718			4382718
	26	Total expenses and disbursements (add lines 24 and 25)	5127968	58441	11989	4893228
	27	(a) Excess of revenue over expenses and disbursements (line 12 minus line 26)	2669343			
		(b) Net investment income (if negative enter -0-)		1282754		
		(c) Adjusted net income (if negative enter -0-)			1015502	

For Paperwork Reduction Act Notice, see page 1 of the Instructions.

Form 990-PF (1984)

9-10-85
FILED

Excise Tax On Investment Income (Section 4940(a), 4940(b), or 4948—one instructions)

1	Domestic organizations enter 2% of line 27(b). Exempt foreign organizations enter 4% of line 27(b)	25655
2	Tax under section 511 (exempt foundations and exempt foreign organizations enter -0-)	25655
3	Add lines 1 and 2	25655
4	Tax under subtitle A (exempt foundations and exempt foreign organizations enter -0-)	25655
5	Tax on investment income (line 3 minus line 4 (but not less than -0-))	25655
6	Credits: (a) Exempt foreign organizations—tax withheld at source	25655
	(b) Tax paid with application for extension of time to file (Form 2758)	25655
7	Tax due (line 5 minus line 6)	None
8	Overpayment (line 6 minus line 5)	None

Balance Sheets		Attached schedules should be for end of year amounts only. (See instructions for col. (C).)		
		Beginning of year	End of year - <i>12/31/84</i>	
		(A) Book Value	(B) Book Value	(C) Fair Market Value
Assets	1 Cash—non-interest bearing	26962	8467	8467
	2 Savings and temporary cash investments	148774	932531	932531
	3 Accounts receivable ▶ <i>See 1</i>	134880		
	minus allowance for doubtful accounts ▶		134880	134880
	4 Pledges receivable ▶			
	minus allowance for doubtful accounts ▶			
	5 Grants receivable			
	6 Receivables due from officers, directors, trustees, and other disqualified persons (see instructions)			
	7 Other notes and loans receivable ▶			
	minus allowance for doubtful accounts ▶			
	8 Inventories for sale or use	24823		
	9 Prepaid expenses and deferred charges	46646284		
	10 Investments—securities (attach schedule)			
	11 Investments—land, buildings, and equipment: basis ▶			
	minus accumulated depreciation (attach schedule) ▶			
	12 Investments—mortgage loans			
13 Investments—other (attach schedule)				
14 Land, buildings, and equipment: basis ▶ <i>See 1</i>	91167			
minus accumulated depreciation (attach schedule) ▶	42984	54883	54883	
15 Other assets (Describe ▶)	148151			
16 Total assets (add lines 1 through 15)	4711999	10973543	10973543	
Liabilities	17 Accounts payable and accrued expenses	600331	140951	
	18 Grants payable			
	19 Support and revenue designated for future periods (attach schedule)			
	20 Loans from officers, directors, trustees, and other disqualified persons			
	21 Mortgages and other notes payable (attach schedule)			
	22 Other liabilities (Describe ▶)			
	23 Total liabilities (add lines 17 through 22)	600331	140951	
Fund Balances or Net Worth	Organizations that use fund accounting, check here ▶ <input type="checkbox"/> and complete lines 24 through 27 and lines 31 and 32.			
	24 (a) Current unrestricted fund			
	(b) Current restricted fund			
	25 Land, buildings, and equipment fund			
	26 Endowment fund			
	27 Other funds (Describe ▶)			
	Organizations not using fund accounting, check here ▶ <input checked="" type="checkbox"/> and complete lines 28-32.			
	28 Capital stock or trust principal	75836991	42819258	
	29 Paid-in or capital surplus			
	30 Retained earnings or accumulated income	29317323	31986666	
31 Total fund balances or net worth (see instructions)	46519668	10832592		
32 Total liabilities and fund balances/net worth (see instructions)	4711999	10973543		

Note 1:

REFER TO STATEMENT 4. ATTACHED

Analysis of Changes in Net Worth or Fund Balances

1	Total net worth or fund balances at beginning of year—Part III, Column (A), line 31	465,966
2	Enter amount from Part I, line 27(a)	126,944
3	Other increases not included in line 2 (itemize) ▶	
4	Add lines 1, 2, and 3	431,525
5	Decreases not included in line 2 (itemize) ▶ <i>Transfer of assets - SCH 4</i>	110,773
6	Total net worth or fund balances at end of year (line 4 minus line 5)—Part III, Column (B), line 31	101,259

Statements Regarding Activities

File Form 4720 if you answer "No" to question 10(b), 11(b), or 14(b) or "Yes" to question 10(c), 12(b), 13(a), or 13(b) unless an exception applies.

- | | Yes | No |
|---|-----|----|
| 1 (a) During the tax year, did you attempt to influence any national, State, or local legislation or did you participate or intervene in any political campaign? | | ✓ |
| (b) Did you spend more than \$100 during the year (either directly or indirectly) for political purposes (see instructions for definition)?
If you answered "Yes" to 1(a), or (b), attach a detailed description of the activities and copies of any materials published or distributed by the organization in connection with the activities. | | ✓ |
| (c) Did you file Form 1120-POL? | | ✓ |
| 2 Have you engaged in any activities which have not previously been reported to the Internal Revenue Service?
If "Yes" attach a detailed description of the activities. | | ✓ |
| 3 Have you made any changes, not previously reported to the IRS, in your governing instrument, articles of incorporation, or bylaws, or other similar instruments?
If "Yes" attach a conformed copy of the changes. | | ✓ |
| 4 (a) Did you have unrelated business gross income of \$1,000 or more during the year?
(b) If "Yes" have you filed a tax return on Form 990-T for this year? | | ✓ |
| 5 Was there a liquidation, termination, dissolution, or substantial contraction during the year?
If "Yes," attach the schedule required by General Instruction I. <i>SEE SCH 4</i> | ✓ | |
| 6 Are the section 508(e) requirements satisfied either:
• by language written into the governing instrument, or
• by State legislation that effectively amends the governing instrument so that no mandatory directions that conflict with the State law remain in the governing instrument? | ✓ | |
| 7 Did you have at least \$5,000 in assets at any time during the year?
If "Yes" complete Part III, Column (C) and Part XIII. | ✓ | |
| 8 (a) Enter States to which the foundation reports or with which it is registered (see instructions) ▶
<i>California, Illinois</i> | | |
| (b) If you answered 7 "Yes" have you furnished a copy of Form 990-PF to the Attorney General (or his or her designate) of each State as required by General Instruction K.1?
If "No" attach explanation. | ✓ | |
| 9 Are you claiming status as an operating foundation within the meaning of section 4942(j)(3) or 4942(j)(5) for calendar year 1984 or fiscal year beginning in 1984 (see instructions for Part XII)?
If "Yes," complete Part XII. | | ✓ |
| 10 Self-dealing (section 4941): | | |
| (a) During the year did you (either directly or indirectly): | | |
| (1) Engage in the sale, or exchange, or leasing of property with a disqualified person? | | ✓ |
| (2) Borrow money from, lend money to, or otherwise extend credit to (or accept it from) a disqualified person? | | ✓ |
| (3) Furnish goods, services, or facilities to (or accept them from) a disqualified person? | | ✓ |
| (4) Pay compensation to or pay or reimburse the expenses of a disqualified person? | | ✓ |
| (5) Transfer any of your income or assets to a disqualified person (or make any of either available for the benefit or use of a disqualified person)? | | ✓ |
| (6) Agree to pay money or property to a government official? (Exception: check "No" if you agreed to make a grant to or to employ the official for a period after he or she terminates government service if he or she is terminating within 90 days.) | | ✓ |
| (b) If you answered "Yes" to any of the questions 10(a)(1) through (6), were the acts you engaged in excepted acts as described in regulations section 53.4941(d)-3 and 4? | | ✓ |
| (c) Did you engage in a prior year in any of the acts described in 10(a), other than excepted acts, that were acts of self-dealing that were not corrected by the first day of your tax year beginning in 1984? | | ✓ |
| 11 Taxes on failure to distribute income (section 4942) (does not apply for years you were an operating foundation as defined in section 4942(j)(3) or 4942(j)(5)): | | |
| (a) Did you at the end of tax year 1984 have any undistributed income (lines 6(d) and (e), Part XI) for tax year(s) beginning before 1984?
If "Yes" list the years ▶ | | ✓ |
| (b) If "Yes" to (a) above, are you applying the provisions of section 4942(a)(2) (relating to incorrect valuation of assets) to the undistributed income for ALL such years? | | ✓ |
| (c) If the provisions of section 4942(a)(2) are being applied to ANY of the years listed in (a) above, list the years here and see the instructions ▶ | | ✓ |

Statements Regarding Activities (continued)**12 Taxes on excess business holdings (section 4943):**

- (a) Did you hold more than 2% direct or indirect interest in any business enterprise at any time during the year? ☒ Yes ☐ No
- (b) If "Yes" did you have excess business holdings in 1984 as a result of any purchase by you or disqualified persons after May 26, 1969; after the lapse of the 5-year period to dispose of holdings acquired by gift or bequest; after the lapse of the 10-year first phase holding period, or after the 15-year first phase holding period? ☒ Yes ☐ No

Note: You may use Schedule C, Form 4720, to determine if you had excess business holdings in 1984.

13 Taxes on investments which jeopardize charitable purposes (section 4944):

- (a) Did you invest during the year any amount in a manner that would jeopardize the carrying out of your charitable purposes? ☒ Yes ☐ No
- (b) Did you make any investment in a prior year (but after December 31, 1969) that could jeopardize your charitable purpose that you had not removed from jeopardy on the first day of your tax year beginning in 1984? ☒ Yes ☐ No

14 Taxes on taxable expenditures (section 4945):

(a) During the year did you pay or incur any amount to:

- (1) Carry on propaganda, or otherwise attempt to influence legislation by attempting to affect the opinion of the general public or any segment thereof, or by communicating with any member or employee of a legislative body, or by communicating with any other government official or employee who may participate in the formulation of legislation? ☒ Yes ☐ No
- (2) Influence the outcome of any specific public election, or to carry on, directly or indirectly, any voter registration drive? ☒ Yes ☐ No
- (3) Provide a grant to an individual for travel, study, or other similar purposes? ☒ Yes ☐ No
- (4) Provide a grant to an organization, other than a charitable, etc., organization described in section 509(a)(1), (2), or (3)? ☒ Yes ☐ No
- (5) Provide for any purpose other than religious, charitable, scientific, literary, or educational purposes, or for the prevention of cruelty to children or animals? ☒ Yes ☐ No

(b) If you answered "Yes" to any of questions 14(a)(1) through (a)(5), were all such transactions excepted transactions as described in regulations section 53.4945? ☒ Yes ☐ No

(c) If you answered "Yes" to question 14(a)(4), do you claim exemption from the tax because you maintained expenditure responsibility for the grant? ☒ Yes ☐ No

If "Yes" attach the statement required.

15 Did any persons become substantial contributors during the tax year?

If "Yes" attach a schedule listing their names and addresses.

16 During this tax year did you maintain any part of your accounting/tax records on a computerized system?**Information About Officers, Directors, Trustees, Foundation Managers, Highly Paid Employees and Contractors****1 List all officers, directors, trustees, foundation managers and, if paid, their compensation for 1984 (see instructions):**

Name and address	Title, and average hours per week devoted to position	Contributions to employee benefit plans	Expense account, other allowances	Compensation
SCHEDULE 5				
Total				18279

2 Compensation of five highest paid employees for 1984 (other than included in 1 above—see instructions):

Name and address of employees paid more than \$30,000	Title, and time devoted to position	Contributions to employee benefit plans	Expense account, other allowances	Compensation
WALTER F. CARLY 1380 MANASSA DR SANTA MONICA CA 90404	6-911764 - Grants Program Full Time	17290	-	45160

Total number of other employees paid over \$30,000 ☒ None

Part X Qualifying Distributions (see instructions)

1 Amounts paid (including administrative expenses) to accomplish charitable, etc., purposes:	
(a) Expenses, contributions, gifts, etc.—total from Part I, column (D), line 26	4893228
(b) Program-related investments	
2 Amounts paid to acquire assets used (or held for use) directly in carrying out charitable, etc., purposes	
3 Amounts set aside for specific charitable projects that satisfy the:	
(a) Suitability test (prior IRS approval required)	
(b) Cash distribution test (attach the required schedule)	
4 Total qualifying distributions made in 1984 (add lines 1, 2, and 3)—also enter in Part XI, line 4	4893228

Part XI Computation of Undistributed Income (see instructions)		(a) Corpus	(b) Years prior to 1983	(c) 1983	(d) 1984
1 Distributable amount for 1984 from Part IX					543062
2 Undistributed income, if any, as of the end of 1983:					
(a) Enter amount for 1983				-	
(b) Total for prior years:			-		
3 Excess distributions carryover, if any, to 1984:					
(a) From 1979	4645092				
(b) From 1980	4541892				
(c) From 1981	3989277				
(d) From 1982	512795				
(e) From 1983	6156775				
(f) Total of 3(a) through (e)		24445831			
4 Qualifying distributions for 1984 4893228					
(a) Applied to 1983, but not more than line 2(a)				-	
(b) Applied to undistributed income of prior years (Election required)			-		
(c) Treated as distributions out of corpus (Election required)		-			
(d) Applied to 1984 distributable amount					543062
(e) Remaining amount distributed out of corpus		4350166			
5 Excess distributions carryover applied to 1984 (If an amount appears in column (d), the same amount must be shown in column (a))					-
6 Enter the net total of each column as indicated below:					
(a) Corpus. Add lines 3(f), 4(c), and 4(e). Subtract line 5		28795997			
(b) Prior years' undistributed income. Line 2(b) minus line 4(b)			(b) -		
(c) Enter the amount of prior years' undistributed income for which a notice of deficiency has been issued, or on which the section 4942(a) tax has been previously assessed			(c) -		
(d) Subtract line 6(c) from line 6(b). Taxable amount—see instructions.			(d) -		
(e) Undistributed income for 1983. Line 2(a) minus line 4(a). Taxable amount—see instructions.				-	
(f) Undistributed income for 1984. Line 1 minus lines 4(d) and 5. This amount must be distributed in 1985					-
7 Amounts treated as distributions out of corpus to satisfy requirements imposed by section 170(b)(1)(D) or 4942(g)(3) (see instructions).					
8 Excess distributions carryover from 1979 not applied on line 5 or line 7 (see instructions)		4645092			
9 Excess distributions carryover to 1985. (Line 6(a) minus lines 7 and 8)		24150905			
10 Analysis of line 9:					
(a) Excess from 1980	4541892				
(b) Excess from 1981	3989277				
(c) Excess from 1982	512795				
(d) Excess from 1983	6156775				
(e) Excess from 1984	4350166				

Private Operating Foundations (See instructions and Part V, question 9) *N/A*

- 1 (a) If the foundation has received a ruling or determination letter that it is an operating foundation, and the ruling is effective for 1984, enter the date of the ruling
- (b) Check box to indicate whether you are an operating foundation described in section ☐ 4942(j)(3) or ☐ 4942(j)(5).

- 2 (a) For 1984, 1983 and 1982, enter the lesser of the adjusted net income from Part I or the minimum investment return from Part VII of the return for each correct year. For 1981, enter the adjusted net income from that return

Tax year		Prior 3 Years			(e) Total
(a) 1984	(b) 1983	(c) 1982	(d) 1981		

Supplementary Information (see instructions)

1 Information Regarding Foundation Managers

- (a) List here any managers of the foundation who have contributed more than 2% of the total contributions received by the foundation before the close of any tax year (but only if they have contributed more than \$5,000). (See section 507(d)(2).)

NONE

- (b) List here any managers of the foundation who own 10% or more of the stock of a corporation (or an equally large portion of the ownership of a partnership or other entity) of which the foundation has a 10% or greater interest.

NONE

2 Information Regarding Contribution, Grant, Gift, Loan, Scholarship, etc., Programs

If you make gifts, grants, awards, (see instructions) etc., to individuals or organizations, check here ☐ and complete these items:

- (a) The name, address, and telephone number of the person to whom applications should be addressed

THE FOUNDATION IS NO LONGER MAKING GRANTS - SEE SCH 4

- (b) The form in which applications should be submitted and information and materials they should include

N/A

- (c) Any submission deadlines

N/A

- (d) Any restrictions or limitations on awards, such as by geographical areas, charitable fields, kinds of institutions, or other factors

N/A

Supplementary Information (continued)

3 Grants and Contributions Paid During the Year or Approved for Future Payment

Recipient Name and address (home or business)	If recipient is an individual, show any relationship to any foundation manager or substantial contributor	Foundation status of recipient	Purpose of grant or contribution	Amount
(a) Paid during year SEE SCHEDULE 1	NO RECIPIENT IS RELATED IN ANY MANNER		SCHEDULE 1	4382718
Total (Enter this amount in Part I, col. (A), line 28)				4382718
(b) Approved for future payment				
Total				NONE

Summary of Grant Programs and Other Activities	(A) Grants and Program-related Investments	(B) Administrative Expenses	(C) Total
1. Gifts, contributions, scholarships and other grants	4382718	519510	4892228
2. Direct charitable activities (describe each):			
(a) 1/4			
(b)			
(c) Direct technical and other assistance to grantees (see instructions)			
(d) All other (attach schedule)			
(e) Total—add (a) through (d)			
3. Program-related investments (describe each type):			
(a)			
(b) 1/4			
(c)			
(d) All other (attach schedule)			
(e) Total—see instructions			
4. Other qualifying distributions			
5. Other expenses not included in lines 1 - 4			234740

Supporting Data

- Describe on an attached schedule the bases (for example, time spent, salary expenses incurred, space utilized, etc.) used to allocate administrative expenses to the activities described in Part XIV-A. 1/4
- For the foundation's principal direct charitable activities and program-related investments provide a schedule of relevant statistical information, such as the number of organizations and other beneficiaries served, conferences convened, research papers produced, etc.
- Attach a schedule for Part XIV-A, lines 2 and 3 setting forth for each activity or investment area the amount of any income produced by it.

Public Inspection

- Enter the date the notice of availability of the annual return appeared in a newspaper ▶ JULY 8, 1985
- Enter the name of the newspaper ▶ SANTA ANITA NEWS PRESS
- Check here ☒ if you have attached a copy of the newspaper notice as required by the instructions. (If the notice is not attached, the return will be considered incomplete.)

Under penalties of perjury, I declare that I have examined this return, including accompanying schedules and statements, and to the best of my knowledge and belief it is true, correct and complete. Declaration of preparer (other than taxpayer or fiduciary) is based on all information of which preparer has any knowledge.

Signature of officer or trustee Robert H. Roe Date July 12, 1985 Title President

Preparer's signature Luciano H. Hanson Date 7/11/85 Check if self-employed ☒ Preparer's social security no. [REDACTED]

Firm's name (or yours, if self-employed) and address COOPER & HANSON, CERTIFIED PUBLIC ACCOUNTANTS E.I. No. 13 521870

401 WEST 9 STREET, SUITE 200, SAN ANTONIO, TX 78201 ZIP code 78201

**In the Superior Court of the State of California
In and for the County of Santa Barbara**

In the Matter of. . . The Kroc Foundation

Public Notice

**PROOF OF PUBLICATION
(2015.5 C.C.P.)**

STATE OF CALIFORNIA }
County of Santa Barbara } ss.

I am a citizen of the United States and a resident of the County aforesaid; I am over the age of eighteen years, and not a party to or interested in the above entitled matter. I am the principal clerk of the printer of the Santa Barbara News-Press, a newspaper of general circulation, printed and published daily in the City of Santa Barbara, County of Santa Barbara, and which newspaper has been adjudged a newspaper of general circulation by the Superior Court of the County of Santa Barbara, State of California, under date of June 9, 1952, Case Number 47171; that the notice herein mentioned was set in type not smaller than nonpareil and was preceded by words printed in black-face type not smaller than nonpareil, describing in general terms the purport and character of the notice intended to be given; that the notice, of which the annexed is a printed copy, has been published in each regular issue of said Santa Barbara News-Press on the following dates, to-wit:

July 8,
.
.

all in the year 19. 85

I hereby certify (or declare) under penalty of perjury that the foregoing is true and correct.

Executed this 8th day of July, 19. 85 . . ., at Santa Barbara, CA.

Marie A. Mayo
Signature

PUBLIC NOTICE
The Annual Return of THE KROC FOUNDATION is available at the First American Title Bldg. 3704 State Street, Suite 312, Santa Barbara, California 93105 for inspection during regular business hours by any citizen who requests it within 180 days of the publication of this notice.
ROBERT L. KROC
President
July 8/85--9492

1/16

GRANTS IN EFFECT
1984

<u>Principal Investigator and Institution</u>	<u>Title of Project</u>	<u>Amount</u>
D. G. Patel, Ph.D. Barbara Kopp Geriatric Research Center	Lack of glucagon response to insulin- hypoglycemia in diabetic rats and its mode of action	\$ 15,400
Dana Giulian, Ph.D. Baylor College of Medicine	Isolation of glial stimulatory factors from regenerating neural tissue	40,000
Ravi Iyengar, Ph.D. Baylor College of Medicine	Development and characterization of monoclonal antibodies against the hepatic glucagon receptor	17,000
Charlotte A. Tate, Ph.D. Baylor College of Medicine	Exercise-induced hypoglycemia in insulin-dependent diabetes mellitus	21,807
Terry B. Strom, M.D. Beth Israel Hospital	The relationship between immunosenescence and responsiveness to insulin and T cell growth factor	9,467
Paul F. Pilch, Ph.D. Boston University	Insulin receptor protein kinase activity	37,333
Jean D. Sipe, Ph.D. Boston University	The role of interleukin 1 in acute and and chronic inflammation	18,266
Howard L. Weiner, M.D. David M. Dawson, M.D. Brigham and Women's Hospital	Outpatient immunosuppressive treatment of multiple sclerosis	26,250
Arnold I. Caplan, Ph.D. Case Western Reserve University	Mesodermal modulating factor	20,000
Richard W. Hanson, Ph.D. Case Western Reserve University	The introduction of an insulin and cAMP regulated gene into whole animals	12,000
Thomas F. Kresina, Ph.D. Case Western Reserve University	A study of the idiotype of anti-collagen antibody molecules and their pathogenesis in experimental immune synovitis	23,000
Vincent M. Monnier, M.D. Robert R. Kohn, Ph.D. Case Western Reserve University	Correlation between browning of skin collagen and long-term sequelae of diabetes	25,588
Nai-Kong V. Cheung, M.D., Ph.D. Case Western Reserve University	The induction of immunologic unresponsiveness to insulin	40,926
Yves Borel, M.D. Children's Hospital, Boston	Preparation of oligonucleotide-protein carrier conjugates	39,000
Allen S. Goldman, M.D. Children's Hospital of Philadelphia	Studies of the mechanism of the diabetic embryopathy	26,250

Schedule 1 2/16

36-6123288

Principal Investigator and Institution	Title of Project	Amount
Pierre DeMeyts, Ph.D. Yoko Fujita Yamaguchi, Ph.D. Rachmiel Levine, M.D. City of Hope Research Institute	Evaluation of the Kinetic properties of the purified insulin receptor	\$ 7,425
Frederick T. Greenaway, Ph.D. Clark University	The role of copper in the action of lysyl oxidase	23,430
David H. Neil, M.R.C.V.S. Colorado State University	Genetic selection for small body size in the Yucatan miniature pig	21,067
Kenneth Sterling, M.D. Columbia University College of Physicians and Surgeons	Effect of thyroid hormone on carbohydrate metabolism	25,905
Collin J. Weber, M.D. Columbia University College of Physicians and Surgeons	Tissue culture isolation and xenotrans- plantation of fetal and neonatal primate and bovine pancreatic islets	30,507
Brian Summers, Ph.D. Cornell University	A study of canine distemper virus in canine cerebellar explants: viral demyelinating encephalitis <u>in vitro</u>	22,761
Peter Hasselbacher, M.D. Dartmouth Medical School	Mechanisms of joint destruction in chronic gout	17,190
Eugene D. Day, Ph.D. Deepak Bastia, Ph.D. Duke University	The production of highly purified human myelin basic protein fragments in <u>E. coli</u> by means of specific oligonucleotide- directed synthesis	31,173
Robert Wondergem, Ph.D. East Tennessee State University	An electrophysiological study of the mechanism of glucagon action in stimu- lating neutral amino acid transport in liver	34,327
David Patterson, Ph.D. Eleanor Roosevelt Institute for Cancer Research	Molecular analysis of genetic regulation of purine synthesis	-0-
John K. Spitznagel, M.D. John S. McDougal, M.D. Emory University	Immunological studies of the arthritis induced in rats by heat-killed strep- tococci	30,000
Allen M. Spiegel, M.D. Foundation for Bio-Medical Research and Education Inc.	Monoclonal antibodies to parathyroid cell surface antigens	4,165
Harry Keen, M.D., F.R.C.P. Guy's Hospital Medical School	Metabolic normalization and microvascular disease	7,816
Dan Eilat, Ph.D. Hadassah University Hospital	Molecular structure and antigenic specificity of SLE hybridoma antibodies	31,812
Miles Fox, M.D. Hallamshire Hospital	Transplantation of rat pancreas and kidney utilizing combined technique and immunological monitoring	12,000

Schedule 1 3/16

36-6125251

<u>Principal Investigator and Institution</u>	<u>Title of Project</u>	<u>Amount</u>
Laurie H. Glimcher, M.D. Harvard School of Public Health	Examination of cell surface structures on the autoreactive T cell by monoclonal antibodies	\$ 22,500
Jack L. Strominger, M.D. Harvard University	Genetic analysis of the HLA-DR region of the human M/C and its relation to multiple sclerosis, juvenile diabetes and rheumatoid arthritis	22,500
Aaron Posner, Ph.D. Joseph M. Lane, M.D. Hospital for Special Surgery	Mineral characterization of osteoporotic bone	7,000
Ronald N. Margolis, Ph.D. Howard University	Glycogen metabolism in liver during development of the rat	22,355
Douglas L. Coleman, Ph.D. The Jackson Laboratory	Evaluation of therapeutic effects of dehydroepiandrosterone on diabetes	16,532
George H. Sack, Jr., M.D., Ph.D. John F. Kennedy Institute	The amyloid genes in arthritis and inflammatory diseases	30,000
Elaine L. Alexander, M.D., Ph.D. Johns Hopkins University	Murine models of immune-mediated central nervous system disease in human rheumatic disorders	39,398
Gihan Tennekoon, M.D. Guy M. McKhann, M.D. Johns Hopkins University	Regulation of myelination by Schwann cells <u>in vitro</u>	42,675
Thomas T. Aoki, M.D. Joslin Research Laboratory	C-peptide kinetics in normal, type I and II diabetes mellitus	-0-
Hans Wigzell, M.D., Ph.D. Lars Klareskog, M.D. Karolinska Institute	Specificity of arthritogenic immune responses	38,500
Neville Marks, Ph.D. The Kline Research Institute	Brain thiol proteinase inhibitors and demyelination conditions	31,330
Wendy B. Macklin, Ph.D. Prescott L. Deininger, Ph.D. Louisiana State University	Isolation of the myelin proteolipid and basic protein genes	27,000
Joseph P. Michalski, M.D. Candace C. McCombs, Ph.D. Louisiana State University	Lymphocyte abnormality underlying a genetic predisposition to autoimmunity	14,740
Lloyd Axelrod, M.D. Massachusetts General Hospital	Regulation of prostacyclin production by isolated adipocytes	21,305
Robert W. Mann, Sc.D. Massachusetts Institute of Technology	Local stress concentration in the pathogenesis of osteoarthritis	24,466

Schedule 1 4/16

36-6126268

Principal Investigator
and InstitutionTitle of ProjectAmount

Alexander Rich, M.D. Massachusetts Institute of Technology	The search for antibodies against nuclear Z-DNA binding proteins in animals and in humans with systemic lupus erythematosus or other autoimmune diseases	\$ 22,952
Thomas A. Huff, M.D. Medical College of Georgia	The relation of non-enzymatic glycosyla- tion of lens crystallin to cataract formation in diabetes	-0-
G. Colin Budd, Ph.D. Ben Pansky, M.D., Ph.D. Medical College of Ohio	Identification of insulin-like immuno- reactivity in cells of the anterior pituitary gland	20,873
William G. Blackard, M.D. Medical College of Virginia	Anti-idiotypic antibodies in insulin treated diabetics	14,961
George H. DeVries, Ph.D. Medical College of Virginia	The influence of axonal membrane on glial cell proliferation and differentiation	10,593
Herman S. Cheung, Ph.D. Medical College of Wisconsin	The role of chondrocytes in the pathogenesis of crystal deposition diseases	8,828
Susan Koethe, Ph.D. Medical College of Wisconsin	Manipulation of immunoregulation by plasmapheresis and other therapies in persons with multiple sclerosis	18,000
Neil S. Mandel, Ph.D. Gretchen S. Mandel, Ph.D. Medical College of Wisconsin	The mechanism of calcium pyrophosphate crystal deposition in pseudogout	-0-
Peter G. Sohnle, M.D. Medical College of Wisconsin	The effect of experimental diabetes mellitus on cutaneous <u>Candida albicans</u> infections	21,668
Jackson B. Pickett, M.D. Medical University of South Carolina	Effect of insulin on neuromuscular transmission	-0-
Ifeanyi J. Arinze, Ph.D. Meharry Medical College	Ontogenesis of glucagon and adrenergic in mammalian liver	35,000
D. G. Patel, Ph.D. Meharry Medical College	Lack of glucagon response to insulin- hypoglycemia in diabetic rats and its mode of action	16,940
David W. Hein, Ph.D. Morehouse School of Medicine	The development of a simple, <u>in vitro</u> method, for human acetylator genotype determination	16,902
Elliot J. Rayfield, M.D. Mount Sinai Medical Center	The mechanism of virus-induced altera- tions in insulin release	-0-

Scottsdale 5/84

36-6125258

<u>Principal Investigator and Institution</u>	<u>Title of Project</u>	<u>Amount</u>
Ira D. Goldfine, M.D. Mount Zion Hospital	Production of antibodies to IgF receptors and non-human insulin receptors	\$ 30,000
Vincent C. Hascall, Ph.D. National Institutes of Health	Proteoglycan metabolism in articular cartilage explant cultures	22,208
George S. Johnson, Ph.D. National Institutes of Health	Modulation of glucocorticoid action by ADP-ribosylation of chromosomal proteins	21,155
Hynda K. Kleinman, Ph.D. National Institutes of Health	Isolation and characterization of a collagen binding protein from cartilage	23,502
David M. Neville, Jr., M.D. National Institutes of Health	The design of anti-T cell monoclonal antibody-ricin conjugates which can be used <u>in vivo</u> as T cell suppressants for the treatment of autoimmune diseases	29,733
Peter Nissley, M.D. National Institutes of Health	Development of monoclonal antibodies to insulin-like growth factor receptors	40,000
William E. Paul, M.D. National Institutes of Health	Preparation of a monoclonal antibody to B cell growth factor	7,336
John H. Freed, Ph.D. National Jewish Hospital and Research Center	Role of Ia antigens in activation of helper T cells	20,625
Vincent Agnello, M.D. New England Medical Center Hospital	Studies on low molecular weight DNA- anti-DNA complexes in systemic lupus erythematosus	21,843
Pankaj D. Mehta, Ph.D. New York State Institute for Basic Research in Mental Retardation	Oligoclonal IgG bands in possible MS and optic neuritis	6,765
Rochelle Hirschhorn, M.D. New York University Medical Center	Adenosine receptors in systemic lupus erythematosus	20,020
David A. Moscatelli, Ph.D. New York University Medical Center	Purification and characterization of an angiogenic factor from retina	7,980
Victor Nussenzweig, M.D. New York University Medical Center	Complement receptor defects in patients with circulating immune complexes	27,456
G. Jeanette Thorbecke, M.D. New York University Medical Center	Studies on the role of auto-anti-idiotypic	15,000
Ronald L. Whisler, M.D. Ohio State University	B cell function in human autoimmunity	19,413

Schedule 1 6/16

36-6125258

<u>Principal Investigator and Institution</u>	<u>Title of Project</u>	<u>Amount</u>
Gerrie A. Leslie, Ph.D. Oregon Health Sciences University	New approaches in understanding biological functions of IgD	\$ 39,925
Charles Howard, Jr., Ph.D. Oregon Regional Primate Research Center	Islet cell antibodies in type II human diabetics	-0-
Barry M. Brenner, M.D. Peter Bent Brigham Hospital (Brigham & Women's Hospital)	Vasoactive hormone - glomerular receptor interactions in experimental diabetes mellitus	20,636
Van C. Mow, Ph.D. Rensselaer Polytechnic Institute	Structure and function of proteoglycans of normal and osteoarthritic cartilage	24,000
Anthony Cerami, Ph.D. The Rockefeller University	Role of 16 α -hydroxyestrone-protein adducts in the pathogenesis of lupus erythematosus	43,144
Palph Steinman, M.D. The Rockefeller University	The contribution of dendritic cells to rheumatoid arthritis	8,000
Darrell Doyle, Ph.D. Roswell Park Memorial Institute	Transfer of the plasma membrane receptor for insulin from hepatocytes to cells not responsive to insulin	-0-
Heinz Kohler, M.D., Ph.D. Roswell Park Memorial Institute	Immunomodulation via idiotype network	28,768
Leonard C. Harrison, M.D. Royal Melbourne Hospital	Chemistry and biological significance of insulin-receptor disulfide exchange	23,823
Eva M. Kohner, M.D., F.R.C.P. Royal Postgraduate Medical School	Metabolic normalization and microvascular disease	8,505
Robert W. Simpson, Ph.D. Rutgers University	Viruses associated with rheumatoid arthritis	42,305
T. Joseph McKenna, M.D. St. Vincent's Hospital	The effect of heparin on the renin- angiotensin-aldosterone axis in diabetic patients	18,750
Joy G. Heitzmann, Ph.D. The Salk Institute	An analysis of self-reactive monoclonal antibodies of multiple sclerosis patients	42,000
Argyrios N. Theofilopoulos, M.D. Scripps Clinic and Research Foundation	Idiotypic network in murine systemic lupus erythematosus and rheumatoid arthritis-like disease	43,068
Martin Sonenberg, M.D., Ph.D. Sloan-Kettering Institute for Cancer Research	Growth hormone fragments and insulin interactions	-0-

Schedule 1 7/6

36-6125257

<u>Principal Investigator and Institution</u>	<u>Title of Project</u>	<u>Amount</u>
Jeffery D. Kocsis, Ph.D. Stanford University	Studies on demyelination in the central nervous system	\$ 25,000
Abdul Matin, Ph.D. Stanford University	Energy metabolism of ureaplasma urealyticum - a possible etiological agent of arthritis	-0-
Bryan D. Myers, M.D. Stanford University	Pathogenesis (and preventability) of diabetic nephropathy	22,000
Gerald M. Reaven, M.D. Stanford University	Abnormal very low density lipoprotein binding in noninsulin dependent diabetes mellitus	26,684
Lawrence Steinman, M.D. Stanford University	The treatment of experimental demyelinating disease with monoclonal antibody to the products of immune response genes and to T cell surface antigens	38,500
Samuel Strober, M.D. Stanford University	Treatment of rheumatoid arthritis with total lymphoid irradiation	12,375
Carol M. Brownschidle, Ph.D. State University of New York	The spontaneously diabetic BB rat: an animal model for the study of the effects of maternal diabetes mellitus on pregnancy, fetal maturation and neonatal health.	2,854
Eugene R. Mindell, M.D. State University of New York	The biology of osteonecrosis of the osteoarthritic femoral head	22,000
Lorne M. Golub, D.M.D., M.Sc. Thomas F. McNamara, Ph.D. State University of New York	The effect of diabetes on gingival collagenase and periodontal disease in germfree and conventional rats	24,953
Arthur D. Rosen, M.D. Max I. Hamburger, M.D. State University of New York	Mechanism of immune tissue damage in multiple sclerosis	36,018
Michael V. Viola, M.D. State University of New York	Purification of a bone resorption stimulation factor from a Pagetic cell line	21,586
Phillip H. Smith, Ph.D. State University of New York	Localization of insulin binding sites in pancreatic islets	18,343
Eddy Karnieli, M.D. Technion Research and Development Foundation	Regulation of glucose transport by insulin in the human adipose cell	5,681
Robert M. Friedman, M.D. Uniformed Services University of the Health Sciences	The role of interferons in systemic lupus erythematosus	21,000

<u>Principal Investigator and Institution</u>	<u>Title of Project</u>	<u>Amount</u>
George B. Brown, Ph.D. University of Alabama in Birmingham	Investigations of the relationships between voltage-sensitive channels and cytoskeletal elements in neurons	\$ 38,331
Martine Anne Jaworski, M.D. University of Alberta	Passive transfer of diabetes mellitus in the BB rat	-0-
Murray Korc, M.D. University of Arizona	Effect of diabetes on epidermal growth factor binding and action in rat pancreas	17,000
John R. J. Sorenson, Ph.D. University of Arkansas for Medical Science	Anti-inflammatory activity of copper complexes	-0-
George W. Jordan, M.D. University of California, Davis	Host defenses in virus induced diabetes mellitus	8,594
Gale A. Granger, Ph.D. University of California, Irvine	Demonstration of lymphocyte effector molecules in the tissue destructive lesions of rheumatoid arthritis	9,644
George A. Gutman, Ph.D. University of California, Irvine	Studies on the serological structure of rat kappa chains using monoclonal anti- bodies	9,756
Michael C. Graves, M.D. University of California, Los Angeles	Cytomegalovirus infection of the Schwann cell	34,639
Jerome M. Hershman, M.D. University of California, Los Angeles	Effect of diabetes mellitus on thyrotropin secretion on rats	20,000
Mary Ann K. Markwell, Ph.D. University of California, Los Angeles	Relationship of gangliosides to the onset of multiple sclerosis	40,000
Paul Shapshak, Ph.D. University of California, Los Angeles	Identification and localization of measles virus genes in multiple sclerosis and control brains utilizing cloned complemen- tary DNA probes	24,757
Wallace W. Tourtellotte, M.D., Ph.D. University of California, Los Angeles	MS CNS IgG synthesis and brain glycolipids	9,900
Anthony W. Norman, Ph.D. University of California, Riverside	Vitamin D, the pancreas and insulin relationships	40,000
Theodore Friedmann, M.D. University of California, San Diego	The molecular basis of X chromosome inactivation	30,000

SCHEDULE 1 9/16

86-6125258

Principal Investigator
and InstitutionTitle of ProjectAmountElvin Harper, Ph.D.
University of California, San
DiegoBiosynthesis of a collagenase inhibitor
in chondrocytes

\$ 12,000

Peter Lampert, M.D.
Clayton A. Wiley, M.D., Ph.D.
University of California, San
DiegoMembrane specializations in human
demyelinating diseases

17,486

Michael G. Rosenfeld, M.D.
University of California, San
DiegoNewly discovered neuroendocrine hormones
in pancreas: function and role in diabetes
mellitus

35,000

J. Edwin Seegmiller, M.D.
University of California, San
DiegoNew approaches to elucidation and treatment
of genetic disorders

12,000

Nathan J. Zvaifler, M.D.
University of California, San
DiegoImmunologic defects in rheumatoid arthritis-
the generation of natural killer-like cyto-
toxic effector cells in the autologous mixed
leukocyte reaction

20,000

Benjamin W. Zweifach, Ph.D.
University of California, San
DiegoContributory factors to deterioration of
microcirculation in diabetes

24,000

William F. Ganong, M.D.
University of California, San
FranciscoRelation of the renin-angiotensin system
to the secretion of growth hormone and
ACTH, and to glucose homeostasis

33,000

Laurence A. Gavin, M.D.
University of California, San
FranciscoSomatostatin - a modulator of T₃ metabolism

35,832

Jon David Levine, M.D., Ph.D.
University of California, San
FranciscoRole of synovial nociceptors in experi-
mental arthritis

38,798

Jay A. Levy, M.D.
University of California, San
FranciscoInfluence of dietary fat on the development
of autoimmune disease

19,891

Robert R. McKendall, M.D.
University of California, San
Francisco

Cytotoxicity in multiple sclerosis

19,355

Donald G. Payan, M.D.
University of California, San
FranciscoThe modulation of human T-lymphocyte
function by C3a(70-77) in rheumatoid
arthritis

35,195

SCHEDULE 1 10/16

36-6125251

<u>Principal Investigator and Institution</u>	<u>Title of Project</u>	<u>Amount</u>
William J. Rutter, Ph.D. University of California, San Francisco	Isolation and characterization of the structure of the insulin receptor gene and the role of the receptor in the insulin response	\$ 41,500
Jack P. Antel, M.D. University of Chicago	Mechanism of defective immunoregulation in multiple sclerosis	31,716
Raymond P. Roos, M.D. University of Chicago	DA virus demyelination and persistence	43,684
Arthur H. Rubenstein, M.D. University of Chicago	Metabolic normalization and microvascular disease	-0-
Richard C. Elder, Ph.D. Katherine G. Tepperman, Ph.D. University of Cincinnati	Uptake, metabolism and toxicity of gold-based anti-arthritis drugs	30,000
Henry N. Claman, M.D. University of Colorado Health Sciences Center	Drug-induced autoantibodies in mice	22,500
William W. Hay, Jr., M.D. University of Colorado Health Sciences Center	Development of an insulin-free fetal lamb model	18,750
Stewart Metz, M.D. University of Colorado Health Sciences Center	Metabolism of arachidonic acid in pancreatic islet cells	7,949
Stephen J. Prowse, Ph.D. University of Colorado Health Sciences Center	Xenotransplantation of pancreatic islet tissue	16,270
David W. Talmage, M.D. University of Colorado Health Sciences Center	The mechanism of the acquired tolerance which develops spontaneously to cultured allografts	19,083
Felix Bronner, Ph.D. Gordon Carmichael, Ph.D. University of Connecticut Health Center	Vitamin D and the processing of the calcium-binding protein	22,500
Steven E. Pfeiffer, Ph.D. Paula Dore-Duffy, Ph.D. University of Connecticut Health Center	Effects of sera, cerebrospinal fluid, and lymphocytes from multiple sclerosis patients on the myelinogenic potential of primary cultures and isolated oligodendrocytes of fetal rat brain	35,429
Lawrence G. Raisz, M.D. University of Connecticut Health Center	Effects of glucocorticoids on bone formation	27,369

<u>Principal Investigator and Institution</u>	<u>Title of Project</u>	<u>Amount</u>
Noel K. Maclaren, M.D. University of Florida	HLA-DR and organ specific autoimmune diseases including insulin dependent diabetes	\$ 40,008
Robert I. Misbin, M.D. University of Florida	Effects of insulin-like growth factors on insulin degradation	14,867
Shozo Izui, M.D. University of Geneva	Genetic and immunopathogenic mechanisms of rheumatic diseases	27,706
John S. Cowdery, M.D. University of Iowa	Enteric antigen administration in a murine model of systemic lupus erythematosus	30,000
Harold P. Schedl, M.D., Ph.D. University of Iowa	Total parenteral nutrition in the diabetic rat: effects on small intestinal mucosal growth and function	14,644
John W. Weiler, M.D. University of Iowa	Complement regulation of <u>in vitro</u> immunoglobulin biosynthesis	21,010
Robert L. Hirsch, Ph.D. Kenneth P. Johnson, M.D. University of Maryland	Effects of cloned alpha interferon on immunoregulation in multiple sclerosis	46,752
Margo P. Cohen, M.D. University of Medicine and Dentistry of New Jersey	Cultured retinal microvessel cells: a model for study of diabetic retinopathy	-0-
Timothy J. Regan, M.D. University of Medicine and Dentistry of New Jersey	Left ventricular function and composition in diabetes after continuous insulin infusion	8,669
John A. Hamilton, Ph.D. University of Melbourne	An in vitro model of rheumatoid arthritis	17,641
Alphonse R. Burdi, Ph.D. Stanley M. Garn, Ph.D. University of Michigan	Prenatal determinants of human fatness and obesity	25,572
Jack L. Kostyo, Ph.D. University of Michigan	The site of the diabetogenic action of growth hormone	-0-
Miriam H. Meisler, Ph.D. University of Michigan	Differential expression of amylase genes in diabetic mice	19,000
Aaron I. Vinik, M.D. University of Michigan	Biologic activity of somatostatin in blood	18,550
Wendell W. Weber, M.D., Ph.D. University of Michigan	The development of a simple, <u>in vitro</u> method for human acetylase genotype determination	25,630

JUNE 20 1984 12/6

JL-6,25253

Principal Investigator
and InstitutionTitle of ProjectAmountJose Barbosa, M.D.
University of MinnesotaStudies of new genetic markers in
insulin dependent diabetes mellitus

\$ 25,000

David M. Brown, M.D.
University of MinnesotaStudies of effects of high protein and
altered fatty acid diets on physiologic
and pathologic manifestations of diabetic
glomerulopathy

40,925

Joel D. Taurog, M.D.
University of MinnesotaProduction of cytolytic human T cell
clones specific for HLA-B27

22,826

Sean O'Regan, M.D.
University of Montreal

DNA anti-DNA nephritis in situ

-0-

Louis Lippiello, Ph.D.
University of NebraskaElectrical enhancement of articular
cartilage regeneration: comparative
effect of pulsing electromagnetic fields
and pulsing direct current

31,545

Ernest L. Mazzaferri, M.D.
University of NevadaGastric inhibitory polypeptide receptors
in adipocytes and pancreatic beta cells

30,244

K.G.M.M. Alberti, M.D.
University of Newcastle Upon
TyneMetabolic normalization and microvascular
disease

3,329

R. Philip Eaton, M.D.
University of New MexicoBioengineering and biomedical development
of a programmable/implantable insulin
delivery system

-0-

Dennis E. Van Epps, Ph.D.
University of New MexicoLymphocyte and neutrophil chemotaxis
in the synovial tissues of patients
with rheumatoid arthritis

25,163

Ralph C. Williams, Jr., M.D.
University of New MexicoStudies of immune dysregulation in
connective tissue diseases

41,937

Allen E. Blaurock, Ph.D.
University of North Carolina
at Chapel HillThe role of two myelin proteins in
stabilizing the structure of the nerve
myelin sheath

-0-

Rogert A. Eisenberg, M.D.
University of North Carolina
at Chapel HillImmune complexes in human disease:
detection, characterization and isolation

19,250

Jeffrey A. Frelinger, Ph.D.
University of North Carolina
at Chapel HillRole of immune response associated Ia
antigens in the brain

-0-

Thomas W. Sadler, Ph.D.
University of North Carolina
at Chapel HillEffects of maternal diabetes on embryonic
metabolism

-0-

<u>Principal Investigator and Institution</u>	<u>Title of Project</u>	<u>Amount</u>
John H. Schwab, Ph.D. University of North Carolina at Chapel Hill	Pathogenesis of arthritis induced by peptidoglycan-polysaccharide complexes of microbial origin	\$ 20,000
Malcolm C. Champion, M.D., F.R.C.P. University of Ottawa	Metabolic normalization and microvascular disease	2,211
Donald H. Gilden, M.D. University of Pennsylvania	Coronavirus A59 induced demyelination	40,584
Abdolmohammad Rostami, M.D., Ph.D. University of Pennsylvania	Studies on Schwann cells, myelin and mechanisms of myelination and demyelin- ation	12,000
John D. Fernstrom, Ph.D. University of Pittsburgh	Effects of diabetes on neutral amino acids and brain neurotransmitters	13,447
Theresa L. Whiteside, Ph.D. Robert B. Buckingham, M.D. University of Pittsburgh	Cloning the scleroderma fibroblast	34,435
Robert Ader, Ph.D. Nicholas Cohen, Ph.D. University of Rochester	Behavioral processes in the immuno- pharmacotherapy of autoimmune disease	-0-
Robert M. Herndon, M.D. University of Rochester	Immunologic and immunoelectron microscopic studies of cerebrospinal fluid in multiple sclerosis	10,541
Kenneth McCormick, M.D. University of Rochester	Maternal diabetes and perinatal hepatic metabolism	-0-
Margaret W. Neuman, Ph.D. University of Rochester	Transcellular transport of calcium in osteoblasts and its role in bone mineralization and calcium homeostasis	19,800
John O. Fleming, M.D. University of Southern California	Coronaviral antigens in multiple sclerosis	17,671
Harvey R. Kaslow, Ph.D. University of Southern California	Regulation of cyclic-nucleotide phospho- diesterase expression	26,170
Ramesh C. Gupta, M.D. University of Tennessee	Identity of antigen(s) in immune complexes	9,625
John M. Stuart, M.D. University of Tennessee	The role of collagen autoimmunity in experimental and rheumatoid arthritis	39,600
Karl Folkers, Ph.D. University of Texas at Austin	Cooperative research on the synthesis of peptides related to the human growth hormone and having diabetogenic activity	-0-

<u>Principal Investigator and Institution</u>	<u>Title of Project</u>	<u>Amount</u>
Karl Folkers, Ph.D. University of Texas at Austin	Synthesis of interferon and fragments	\$ -0-
John R. Falck, Ph.D. University of Texas Health Science Center	Novel pancreatic eicosanoids	39,918
J. Donald Smiley, M.D. University of Texas Health Science Center	Calcinosis in scleroderma and similar conditions	14,894
Grady F. Saunders, Ph.D. University of Texas System Cancer Center	Biosynthesis of glucagon	-0-
Ellen L. Simpson, Ph.D. John W. Jacobs, Ph.D. Gregory R. Mundy, M.D. University of Texas Health Science Center	Osteoclast activating factor synthesis in rheumatoid arthritis	19,843
John I. Stevens, Ph.D. University of Toronto	Three dimensional cytoarchitecture and quantitative analysis of diabetic peripheral axons	8,333
Barry C. Cole, Ph.D. University of Utah	Interaction of a mycoplasma mitogen with Ia antigens: role in disease pathogenesis and immunological dysfunction	19,230
Allen B. Edmundson, Ph.D. University of Utah	The application of X-ray crystallography to human rheumatoid arthritis	7,000
Seth H. Pincus, M.D. University of Utah	Genetic mechanisms of idotype suppression	6,000
Johannes Veldhuis, M.D. University of Virginia	Actions of insulin on ovarian cells	22,437
John Dupre, M.D. University of Western Ontario	Metabolic normalization and microvascular disease	1,100
Matthew D. Davis, M.D. University of Wisconsin	Metabolic normalization and microvascular disease	4,350
Ian D. Duncan, Ph.D. University of Wisconsin	An immunocytochemical study of myelin formation in a canine myelin mutant	32,068
Nada A. Abumrad, Ph.D. Charles R. Park, M.D. Jane H. Park, Ph.D. Vanderbilt University	Transport of long chain FA: effects of insulin and diabetes	21,000

<u>Principal Investigator and Institution</u>	<u>Title of Project</u>	<u>Amount</u>
Kenneth L. Brigham, M.D. Vanderbilt University	Mechanisms of inflammatory injury: interactions between granulocytes and vascular endothelium	\$ 22,000
Eve P. Reaven, Ph.D. Veterans Administration Medical Center	Effect of age and related environ- mental variables on insulin secretion and action in the rat	27,588
Paul E. Lacy, M.D. Washington University	Transplantation of islets of Langerhans in primates	45,000
Jay M. McDonald, M.D. Washington University	Insulin regulation of glucose transport in adipocytes	12,000
Philip Osdoby, Ph.D. Washington University	Osteoclast development and function in systemic and inflammatory bone disease	17,177
Alan M. Permutt, M.D. Washington University	Insulin gene studies in families with non-insulin dependent diabetes	40,000
Gale W. Rafter, Ph.D. West Virginia University Medical Center	Interleukin 1 and anti-rheumatic drugs	-0-
Luciano G. Frigeri, Ph.D. Whittier Institute for Diabetes and Endocrinology	A new animal model for studying the metabolic actions of pituitary peptides	33,000
F. Arthur McMorris, Ph.D. The Wistar Institute	Regulation of myelination at the molecular level	40,001
David J. Giron, Ph.D. Wright State University	Enhancement of EMC virus by insulin: mechanisms of action	10,415
John Booss, M.D. Yale University	Immunosuppression of B cell function in multiple sclerosis	-0-
John A. Hardin, M.D. Yale University	Analysis of antideoxyribonucleoprotein antibodies from patients with SLE	22,000
Robert S. Sherwin, M.D. Yale University	Metabolic normalization and micro- vascular disease	27,792

TOTAL GRANTS

\$4,343,343

<u>Number of Grants</u>	<u>Disease Area</u>	<u>Amount</u>
83	Arthritis	\$1,740,843
94	Diabetes	1,657,288
36	Multiple Sclerosis	945,212
213		\$4,343,343

CONTRIBUTIONS

1984

<u>DATE</u>	<u>INSTITUTION</u>	<u>AMOUNT</u>	<u>CHECK #</u>
January	Medical Foundation of Buffalo	\$ 2,000.00	12876
	6th International Workshop Calcified Tissue	2,500.00	12916
	Alzheimer's Disease & Related Disorders	100.00	12917
	University of Connecticut Foundation	5,000.00	12918
	Western Association of Physicians - Cannel	1,000.00	12919
	March of Dimes	100.00	12956
February	Research to Prevent Blindness	100.00	13000
March	Professor Fred Rasmussen	100.00	13106
	Arthritis Foundation-Santa Barbara	50.00	13110
April	Gordon Research	2,000.00	13132
	Endocrine Society	7,500.00	13133
	John J.B. Anderson (Roy Talmage)	500.00	13134
	Santa Barbara Firefighters Association	25.00	13157
	Washington University - Paul Lacy Day	1,000.00	13168
	American Diabetes Association - Lopaty Dinner	1,000.00	13167
May	Whittier Institute	200.00	13226
	Regents, UCLA - Conference - Aluminum Related Diseases	2,500.00	13235
June	None		
July	American Thyroid Association	3,500.00	13347
August	Indiana University Foundation-Sonneborn Lecture	500.00	13408
	Dunn School Library - Memorial Barbara Pettley	100.00	13412
October	Medical Foundation Buffalo - Vivian Cody Research	2,000.00	13507
November	Foundation for Advancement Education in Sciences	5,000.00	13543
	Membrane Transport Symposium	2,500.00	13570
December	Research to Prevent Blindness	100.00	13617

TOTAL CONTRIBUTIONS

39,375

TOTAL OF SCHEDULE 1 -

GRANTS & CONTRIBUTIONS

\$ 4,382,718

YEAR ENDED 1984

ACCOUNTANT STATIONERS & PRINTERS, LOS ANGELES

NAME THE KROC FOUNDATIONIDENTIFICATION NO. 26-6125253STATEMENT NO. 5YEAR ENDED 12/31/80

STATEMENTS RE. OFFICIALS, COMPENSATION, ETC.	TITLE & AGE HAS	CONTRIB TO LA BEN PLAN	EXPENSE ACCOUNT	COMPENSATION
RALPH H KROC (deceased 1/14/80)	Chairman of the	None	None	None
1957 Villa La Jolla Dr. Suite 201	Board Member			
14 Jolla Ct 92037	- Nominal			
ROBERT L KROC	President	86,600	22,587	70,000
4737 Sierra Madre Rd	Director			
Santa Barbara CA 93110	- Full			
JOHN R KROC	Vice President	None	None	None
1957 Villa La Jolla Dr. Suite 201	- Director			
14 Jolla Ct 92037	- Part			
FRED L TURNER	Vice President	None	None	None
70 McQuinnos Corporation	- Director			
McQuinnos Pkwy. Oxnard CA 93031	- Nominal			
LORRAINE E GRON	Treasurer	None	None	None
17715 Gulf Blvd #342	Director			
Redington Shores FL 33708	- Nominal			
BILLIE F SMITH	Secretary	None	None	None
Po Box 2000	Director			
San Diego CA 92120	- Nominal			
N TREESTICK	Assistant	None	None	None
1957 Villa La Jolla Dr. Suite 201	Secretary			
14 Jolla Ct 92037	- Part			
JOHN LAWRENCE	Assistant	751	None	18,279
1998 Alamo Pintado Rd	Secretary			
Solvang CA 94968	- Full			
		17,551	22,587	18,279

NAME THE KROC FOUNDATIONIDENTIFICATION NO. 36-6125258STATEMENT NO. 6 Pg 1 of 3YEAR ENDED 1984

SHARES	DESCRIPTION	LOT #	DATE ACQUIRED	DATE SOLD	ORIGINAL COST	GROSS PROCEEDS	ADJUSTED COST	GAIN OR LOSS-LONG	LOSS-SHORT
400	DUN & BRADSTREET CORP	S004	09/06/74	07/26/84	3886	23350	3983	19367	
1000	DUN & BRADSTREET CORP	S004	09/06/74	07/26/84	9777	58375	10019	48356	
800	GEICO CORP	S001	04/08/82	07/26/84	21404	39600	21589	18011	
600	GENERAL ELECTRIC	S005	09/10/75	07/26/84	10303	29775	10484	19291	
30000	INT PAP CV(BARD) 04.250 11/01/86	S001	04/13/82	07/26/84	26550	26400	26550	150-	
800	MAGIC CHEF	S001	05/26/83	07/26/84	24500	20200	24653	4453-	
750	MULTIMEDIA	S001	11/03/82	07/26/84	21125	28313	21125	7188	
20000	NORTHWT AIRLNS CV 07.500 12/15/07	S001	04/14/83	07/26/84	21600	18450	21600	3150-	
1181	SR&F T-E BD FD	S008	04/01/82	07/26/84	7209	8994	7209	1785	
.8260									
3453	SR&F T-E BD FD	S008	03/30/82	07/26/84	21000	26285	21000	5285	
.9470									
838	SR&F T-E BD FD	S008	12/24/80	07/26/84	5734	6380	5734	646	
.3450									
6369	SR&F T-E BD FD	S008	04/19/82	07/26/84	40000	48471	40000	8471	
.4270									
1283	SR&F T-E BD FD	S008	01/04/82	07/26/84	7365	9765	7365	2400	
.1860									
1425	SR&F T-E BD FD	S008	07/01/82	07/26/84	8855	10851	8855	1996	
.8730									
856	SR&F T-E BD FD	S008	07/01/81	07/26/84	5756	6518	5756	762	
.4880									
124	SR&F T-E BD FD	S008	01/02/81	07/26/84	861	949	861	88	
.7140									
1390	SR&F T-E BD FD	S008	07/02/84	07/26/84	10237	10584	10237		347
.8640									
1388	SR&F T-E BD FD	S008	10/03/83	07/26/84	10847	10569	10847		278-
.8400									
1419	SR&F T-E BD FD	S008	10/01/82	07/26/84	10234	10801	10234	567	

NAME THE KROE FOUNDATIONIDENTIFICATION NO. 36-6125258STATEMENT NO. 6 16 2 0 3YEAR ENDED 1984

SHARES	DESCRIPTION	LOT #	DATE ACQUIRED	DATE SOLD	ORIGINAL COST	GROSS PROCEEDS	ADJUSTED COST	GAIN OR LONG	LOSS-SHORT
.3520									
.5136	SR&F T-E BD FD	S008	10/02/81	07/26/84	30000	39092	30000	9092	
.9880									
.1421	SR&F T-E BD FD	S008	01/03/84	07/26/84	10948	10820	10948		128-
.7780									
.1280	SR&F T-E BD FD	S008	04/04/83	07/26/84	10092	9746	10092	346-	
.7110									
.1443	SR&F T-E BD FD	S008	01/03/83	07/26/84	10924	10982	10924	58	
.0480									
.24039	SR&F T-E BD FD	S008	12/19/80	07/26/84	160105	182943	160105	22838	
.7590									
.1456	SR&F T-E BD FD	S008	04/02/84	07/26/84	11200	11083	11200		117-
.4370									
.1293	SR&F T-E BD FD	S008	07/01/83	07/26/84	10106	9847	10106	259-	
.9510									
.820	SR&F T-E BD FD	S008	04/01/81	07/26/84	5727	6244	5727	517	
.4440									
.9174	SR&F T-E BD FD	S008	08/13/82	07/26/84	60000	69817	60000	9817	
.3120									
.1027	SR&F T-E BD FD	S008	10/01/81	07/26/84	5968	7817	5968	1849	
.2480									
.2069	STEINROE UNIVERSE FD INC	S006	04/19/82	07/26/84	25000	29704	25000	4704	
.9640									
.1302	STEINROE UNIVERSE FD INC	S006	04/14/83	07/26/84	25000	18687	25000	6313-	
.2520									
.201	STEINROE UNIVERSE FD INC	S006	07/20/83	07/26/84	4410	2896	4410	1514-	
.8180									
.3468	STEINROE UNIVERSE FD INC	S006	06/10/81	07/26/84	50000	49775	50000	225-	
.6080									
.180	TEMPLE INLAND INC	S001	06/16/83	07/26/84	7981	4860	8026	3166-	
.500	TIME INC	S001	06/16/83	07/26/84	29724	17688	29855	12167-	
.50000	US TREAS NTS	13.000	11/15/90	S004 11/18/80 07/26/84	51344	49969	51344	1375-	

NAME THE KROC FOUNDATIONIDENTIFICATION NO. 36-6125258STATEMENT NO. 6 P. 3 of 3YEAR ENDED 1984

SHARES	DESCRIPTION	LOT #	DATE ACQUIRED	DATE SOLD	ORIGINAL COST	GROSS PROCEEDS	ADJUSTED COST	GAIN OR LOSS-LONG	LOSS-SHORT
1500	AMERICAN GENL CORP	S001	11/09/82	07/26/84	26566	29813	26687	3126	
900	AMP	S001	05/17/82	07/26/84	16494	25650	16675	8975	
1600	BALL CORP	S002	12/29/81	07/26/84	26765	48375	27024	21351	
1050	BROWNING FERRIS	S005	03/24/81	07/26/84	23170	32812	23381	9431	
500	CALFED INC \$4.75 CV PFD	S001	01/19/84	07/26/84	26063	17250	26189		8939-
200	CAPITAL CITIES COMM	S006	11/04/71	07/26/84	4431	31250	4492	26758	
400	CAPITAL CITIES COMM	S006	09/29/71	07/26/84	9641	62500	9763	52737	
500	CARPENTER TECHNOLOGY CORP	S001	01/20/84	07/26/84	27800	18813	27936		9123-
800	CHARMING SHOPPES INC	S001	08/11/83	07/26/84	21120	15900	21120		5220-
800	DATAPRODUCTS	S001	08/17/83	07/26/84	20100	12800	20212		7412-
600	DAYTON HUDSON	S002	01/11/83	07/26/84	15498	18525	15637	2888	
25000	DENNYS CV	09.500 10/15/07 S001	10/21/82	07/26/84	26094	28188	26094	2094	
550	ZAYRE CORP	S001	09/09/83	07/26/84	22550	19938	22694		2756-

Totals }

Total Net Gain

1,044,710 <33,626>
1,288,414 277,330
243,704